Share this page: More

Kelly E. Dooley


Department Affiliation: Primary: Medicine, Divisions of Clinical Pharmacology and Infectious Diseases; Secondary:  Pharmacology and Molecular Sciences
Degree: M.D., Duke University; Ph.D., Johns Hopkins Bloomberg School of Public Health
Rank: Professor
Telephone Number: 410-287-0517
Fax Number: 410-614-9978
E-mail address:
School of Medicine Address: Osler 508, 600 N. Wolfe Street, Baltimore, MD 21287

Clinical pharmacology of anti-infective agents; Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV

Research focuses on tuberculosis (TB) therapeutics with a focus on: (1) Clinical trials of new or existing anti-TB drugs for treatment of drug-sensitive or drug-resistant TB; (2) Clinical pharmacology, pharmacokinetics and pharmacodynamics of anti-TB drugs and regimens; (3) co-treatment of TB and HIV; and (4) evaluation of TB and HIV drugs in special populations, such as pregnant women and children; (5) Translational work involving novel animal models of TB disease; and (6) optimizing anti-mycobacterial therapeutics for areas of special unmet medical need, including TB meningitis (TBM) and nontuberculous mycobacteria.


Representative Publications:

  • Dooley, K.E., Luetkemeyer, A.F., Park, J.-G., Allen, R., Cramer, Y., Murray, S., Sutherland, D., Aweeka, F., Koletar, S.L., Marzan, F., Bao, J., Savic, R., Haas, D.W., and the ACTG A5306 Study Team. Phase I safety, pharmacokinetics, and pharmacogenetics study of the anti-tuberculosis drug PA-824 with concomitant lopinavir/ritonavir, efavirenz, or rifampin. Antimicrobial Agents and Chemotherapy 58: 5245-5252, 2014.  Pub Med Reference
  • Svensson, E.M., Dooley, K.E., Karlsson, M.O. Impact of lopinavir/ritonavir or nevirapine on bedaquiline exposures: potential implications for patients with TB/HIV co-infection. Antimicrobial Agents and Chemotherapy 58: 6406-6412, 2014. Pub Med Reference
  • Dooley, K.E., Denti, P., Martinson, N., Cohn, S., Mashabela, F., Hoffmann, J., Haas, D.W., Hull, J., Msandiwa, R., Castel, S., Wiesner, L., Chaisson, R.E., McIlleron, H. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. Journal of Infectious Diseases 211: 197-205, 2015. Pub Med Reference
  • Dorman, S.E., Savic, R.M., Goldberg, S., Stout, J.E., Schluger, N., Muzanyi, G., Johnson, J.L., Nahid, P., Hecker, E.J., Heilig, C.M., Bozeman, L., Feng, P.-J., Moro, R.N., Mac Kenzie, W., Dooley, K.E., Nuermberger, E.L., Vernon, A., Weiner, M., and the Tuberculosis Trials Consortium.  Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial. American Journal of Respiratory and Critical Care Medicine 191: 333-343, 2015. Pub Med Reference
  • Dooley, K.E., Savic, R., Park, J.-G., Cramer, Y., Hafner, R., Hogg, E., Jank, J., Marzinke, M.A., Patterson, K., Benson, C.A., Hovind, L., Dorman, S.E., Haas, D.W., and the ACTG A5311 Study Team.  Novel dosing strategies increase exposures of the potent anti-tuberculosis drug rifapentine but are poorly tolerated in healthy volunteers: AIDS Clinical Trials Troup Study A5311. Antimicrobial Agents and Chemotherapy 59: 3399-3405, 2015. Pub Med Reference
  • Savic, R., Ruslami, R., Aarnoutse, R., Hesseling, A., Ramachandran, G., Ganiem, A.R., Swaminathan, S., McIlleron, H., Gupta, A., Thakur, K., van Crevel, R., Dooley, K.E.  Pediatric tuberculous meningitis: model-based approach to determining optimal doses of anti-tuberculosis drugs for children.  Clinical Pharmacology and Therapeutics 98: 622-629, 2015. Pub Med Reference
  • Denti, P., Martinson, N., Cohn, S., Mashabela, F., Hoffmann, J., Msandiwa, R., Castel, S., Wiesner, L., Chaisson, R.E., McIlleron, H., Dooley, K.E., and the Tshepiso Study Team. Population pharmacokinetics of rifampicin in pregnant women with tuberculosis and HIV co-infection in Soweto, South Africa. Antimicrobial Agents and Chemotherapy 60: 1234-1241, 2015. Pub Med Reference
  • Bartelink, I.H., Zhang, N., Keizer, R.J., Strydom, N., Converse, P.J., Dooley, K.E., Nuermberger, E.L., Savic, R.M.  New paradigm for translational modeling to predict long-term tuberculosis treatment response. Clin Transl Sci 10:366-379, 2017. Pub Med Reference
  • Denti, P., Garcia-Prats, A.J., Draper, H.R., Wiesner, L., Winckler, J., Thee, S., Dooley, K.E., Savic, R.M., McIlleron, H.M., Schaaf, H.S., Hesseling, A.C.  Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.  Antimicrobial Agents and Chemotherapy 62:e01521-27, 2018. Pub Med Reference
  • Rifat, D., Prideaux, B., Savic, R.M., Urbanowski, M.E., Parsons, T.L., Luna, B., Marzinke, M.A., Ordonez, A.A., Demarco, V.P., Jain, S.K., Dartois, V., Bishai, W.R., Dooley, K.E.  Using rabbits with cavitary disease and translational PK/PD modeling to understand TB trial results. Science Translational Medicine 10(435). eaai7886, 2018. Pub Med Reference
  • Alfarisi, O., Mave, V., Gaikwad, S., Sahasrabudhe, T., Ramachandran, G., Kumar, H., Gupte, N., Kulkarni, V., Deshmukh, S., Atre, S., Raskar, S., Lokhande, R., Barthwal, J., Kakrani, A., Gupta, A., Golub, J.E., Dooley, K.E. The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.  Antimicrobial Agents and Chemotherapy 62(11) e01382-18, 2018. Pub Med Reference
  • Radtke, K.K., Dooley, K.E., Dodd, P.J., Garcia-Prats, A.J., McKenna, L., Hesseling, A.C., Savic, R.M. Evaluation of dosing guidelines for childhood tuberculosis: a mathematical modeling study. Lancet Child & Adolescent Health 3:636-645, 2019. Pub Med Reference
  • Paradkar, M., Devaleenal, D.B., Mvalo, T., Arenivas, A., Thakur, K.T., Afrin, S., Giridharan, P., Selladurai, E., Kinikar, A., Valvi, C., Gupta, A., Mave,V., Dooley, K.E. Challenges in conducting trials for pediatric tuberculous meningitis: lessons from the field. International Journal Tuberculosis and Lung Disease 23: 1082-1089, 2019. Pub Med Reference
  • Tucker, E.W., Pieterse, L., Zimmer, M.D., Udwadia, Z.F., Peloquin, C.A., Gler, M.T., Ganatra, S., Tornheim, J.A., Chawla, P., Caoili, J.C., Ritchie, B., Jain, S.K., Dartois, V., Dooley, K.E.  Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans.  Antimicrobial Agents and Chemotherapy 63: e00913-19, 2019. Pub Med Reference
  • Hong, H., Dowdy, D.W., Dooley, K.E., Francis, H.W., Budhathoki, C., Han, H.R., Farley, J.E. Aminoglycoside-induced hearing loss among patients being treated for drug-resistant tuberculosis in South Africa: a prediction model. Clinical Infectious Diseases 70(5):917-924, 2019. Pub Med Reference
  • Dooley, K.E., Kaplan, R., Mwelase, N., Grinsztejn, B., Ticona, E., Lacerda, M., Sued, O., Belonosova, E., Ait-Khaled, M., Angelis, K., Brown, D., Singh, R., Talarico, C.L., Tenorio, A.R., Keegan, M.R., Aboud, M., and the INSPIRING study group.  Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial.  Clinical Infectious Diseases 70(4):549-556, 2020. Pub Med Reference
  • Dooley, K.E., Savic, R., Gupte, A., Marzinke, M.A., Zhang, N., Edward, V.A., Wolf, L., Sebe, M., Likoti, M., Fyvie, M.J., Shibambo, I., Beattie, T., Chaisson, R.E., Churchyard, G.J., and the DOLPHIN Study Team.  Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: A Phase I/II clinical trial. Lancet HIV, 2020. Pub Med Reference
  • Dooley, K.E., Miyahara, S., von Groote-Biglingmaier, F., Sun, X., Hafner, R., Rosenkranz, S.L., Ignatius, E.H., Nuermberger, E.L., Moran, L., Donahue, K., Swindells, S., Vanker, N., Diacon, A.H., and the A5312 Study Team. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020. Pub Med Reference
  • Bigelow, K.M., Deitchman, A.N., Li, Si-Yang, Barnes-Boyle, K., Tyagi, S., Soni, H., Dooley, K.E., Savic, R., Nuermberger, E.L. Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis. Journal of Infectious Diseases, 2020. Pub Med Reference
  • Salazar-Austin, N., Cohn, S., Lala, S., Waja, Z., Dooley, K.E., Hoffmann, C.J., Chaisson, R.E., Martinson, N., and the TSHEPISO study team. Isoniazid preventive therapy and pregnancy outcomes in HIV-infected women in the Tshepiso cohort. Clinical Infectious Diseases, 2020. Pub Med Reference


Other graduate programs in which Dr. Dooley participates: None